Hongkong XinRunde Chemical Co., Ltd

 

Reliable Manufacturer and Supplier of Top Quality Pharmaceutical Raw Material and Pharmaceutical Intermediate

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
News
Home ProductsResearch Chemical Powder

341031-54-7 Sunitinib Malate For The Treatment Of Pancreatic Neuroendocrine Tumors

341031-54-7 Sunitinib Malate For The Treatment Of Pancreatic Neuroendocrine Tumors

341031-54-7 Sunitinib Malate For The Treatment Of Pancreatic Neuroendocrine Tumors
341031-54-7 Sunitinib Malate For The Treatment Of Pancreatic Neuroendocrine Tumors 341031-54-7 Sunitinib Malate For The Treatment Of Pancreatic Neuroendocrine Tumors

Large Image :  341031-54-7 Sunitinib Malate For The Treatment Of Pancreatic Neuroendocrine Tumors Get Best Price

Product Details:
Place of Origin: China
Brand Name: XRD
Certification: GMP
Model Number: 341031-54-7
Payment & Shipping Terms:
Minimum Order Quantity: negotiable
Price: Inquiry for Negotiable
Packaging Details: 1-2 kg / aluminum foil bag, 25kg/ drum, as required
Delivery Time: 1-2days after payment received
Payment Terms: T/T bank, Western Union, Bitcoin, Etc
Supply Ability: 100KG/ Month
Detailed Product Description
CAS: 341031-54-7 Product Name: Sunitinib Malate
Type: Anti Tumor Drugs Appearance: White To Yellow Powder
Usage: Anti Cancer Alias: SU 011248
Assay: 99% Key Words: Sunitinib Malate
High Light:

lab research chemicals

,

research chemicals

Anti Tumor Drugs Sunitinib Malate Cancer Treatment API 341031-54-7 Anti Cancer
 

Description:

 

Name: 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-

Superlist Name: Sunitinib

CAS No.: 557795-19-4

Specification: 99%

Formula: C22H27FN4O2

Molecular Weight: 398.47

Density: 1.23 g/cm3

Melting Point: 189-191 °C

Boiling Point: 572.136 °C at 760 mmHg

Flash Point: 299.818 °C

Appearance: white to yellow powder

 

 

Sunitinib malate Use

Sunitinib malate plays a role in the treatment by preventing cancer cells from getting blood and nutrients needed for growth. Clinical trials show that the medicine can delay the gastrointestinal stromal tumor's growth speed, and can reduce the size of renal cell cancer.

Sunitinib malate is the first the new target drug to selectively according to multiple receptor tyrosine kinases, combined with the two function mechanism which terminate the formation of anti angiogenesis which provide blood to tumor cellss and the anti-tumor which directly attack tumor cells.

It represents a new round of the advent of targeted therapies, not only directly attack the tumor, nor have conventional chemotherapy toxicity reaction.

 

341031-54-7 Sunitinib Malate For The Treatment Of Pancreatic Neuroendocrine Tumors 0

 

COA 




Item of analysis
Standard Result of analysis
Description White to pale yellow powder Conforms
Melting piont 215.0-227.0ºc 219.0-220.0ºc
Identification A:IR Conresponding to reference spectrum Conresponding to reference spectrum
  B :HPLC Conresponding to reference rt Conresponding to reference rt
Loss on drying ≤0.5% 0.31%
Residual on lgnition ≤0.5% 0.19%
Residual solvent Pyridine ≤4000ppm ND
  DMF ≤3000ppm ND
  Chloroform ≤4000ppm ND
Ordinary impurities Total impurities≤2.0% 0.30%
Assay 98.0%~101.0% 99.7%


 

341031-54-7 Sunitinib Malate For The Treatment Of Pancreatic Neuroendocrine Tumors 1

Mechanism of action

Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs).

These include all receptors for platelet-derived GF (PDGF-Rs) and vascular endothelial GF receptors (VEGFRs), which play a role in both tumor angiogenesis and tumor cell proliferation. The simultaneous inhibition of these targets therefore reduces tumor vascularization and triggers cancer cell apoptosis and thus results in tumor shrinkage.

Sunitinib also inhibits CD117 (c-KIT), the receptor tyrosine kinase that (when improperly activated by mutation) drives the majority of gastrointestinal stromal cell tumors. It has been recommended as a second-line therapy for patients whose tumors develop mutations in c-KIT that make them resistant to imatinib, or who the cannot tolerate the drug.

In addition, sunitinib binds other receptors.These include:

RET
CD114
CD135
The fact that sunitinib targets many different receptors, leads to many of its side effects such as the classic hand-foot syndrome, stomatitis, and other dermatologic toxicities.

 

 

Anti Tumor Drugs Sunitinib Malate Cancer Treatment API 341031-54-7 Anti Cancer

Contact Details
Hongkong XinRunde Chemical Co., Ltd

Contact Person: bruce

Tel: +8618874586545

Send your inquiry directly to us